JP2017535559A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2017535559A5 JP2017535559A5 JP2017526844A JP2017526844A JP2017535559A5 JP 2017535559 A5 JP2017535559 A5 JP 2017535559A5 JP 2017526844 A JP2017526844 A JP 2017526844A JP 2017526844 A JP2017526844 A JP 2017526844A JP 2017535559 A5 JP2017535559 A5 JP 2017535559A5
- Authority
- JP
- Japan
- Prior art keywords
- oxobenzo
- triazin
- acetamide
- ethyl
- methoxy
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- -1 hydroxy, amino Chemical group 0.000 claims 194
- 150000001875 compounds Chemical class 0.000 claims 50
- 150000003839 salts Chemical class 0.000 claims 40
- DLFVBJFMPXGRIB-UHFFFAOYSA-N Acetamide Chemical compound CC(N)=O DLFVBJFMPXGRIB-UHFFFAOYSA-N 0.000 claims 16
- 239000003814 drug Substances 0.000 claims 16
- RRXSYZFVDIRTFB-UHFFFAOYSA-N C[CH]C1=CC=C(OC)C=C1 Chemical group C[CH]C1=CC=C(OC)C=C1 RRXSYZFVDIRTFB-UHFFFAOYSA-N 0.000 claims 15
- 125000000217 alkyl group Chemical group 0.000 claims 13
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims 10
- 229910052739 hydrogen Inorganic materials 0.000 claims 9
- 239000001257 hydrogen Substances 0.000 claims 9
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 8
- 125000000876 trifluoromethoxy group Chemical group FC(F)(F)O* 0.000 claims 8
- 125000003545 alkoxy group Chemical group 0.000 claims 7
- GZSKABYYCABBFU-UHFFFAOYSA-N n-(4-oxo-1,2,3-benzotriazin-3-yl)acetamide Chemical compound C1=CC=C2C(=O)N(NC(=O)C)N=NC2=C1 GZSKABYYCABBFU-UHFFFAOYSA-N 0.000 claims 7
- 125000005843 halogen group Chemical group 0.000 claims 6
- 150000002431 hydrogen Chemical class 0.000 claims 6
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims 5
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims 5
- 125000004093 cyano group Chemical group *C#N 0.000 claims 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 4
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 3
- 125000004786 difluoromethoxy group Chemical group [H]C(F)(F)O* 0.000 claims 3
- 125000004785 fluoromethoxy group Chemical group [H]C([H])(F)O* 0.000 claims 3
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 claims 3
- 208000011117 substance-related disease Diseases 0.000 claims 3
- AOPMTWFMINSQGV-UONOGXRCSA-N (2R)-N-[(1S)-1-(2-methoxy-4-methylphenyl)ethyl]-2-(4-oxo-1,2,3-benzotriazin-3-yl)propanamide Chemical compound COC1=C(C=CC(=C1)C)[C@H](C)NC([C@@H](C)N1N=NC2=C(C1=O)C=CC=C2)=O AOPMTWFMINSQGV-UONOGXRCSA-N 0.000 claims 2
- NHHIFMSLOXYVBO-ZDUSSCGKSA-N 2-(4-oxo-1,2,3-benzotriazin-3-yl)-n-[(2r)-2-phenylpropyl]acetamide Chemical compound C1([C@H](CNC(=O)CN2C(C3=CC=CC=C3N=N2)=O)C)=CC=CC=C1 NHHIFMSLOXYVBO-ZDUSSCGKSA-N 0.000 claims 2
- NHHIFMSLOXYVBO-CYBMUJFWSA-N 2-(4-oxo-1,2,3-benzotriazin-3-yl)-n-[(2s)-2-phenylpropyl]acetamide Chemical compound C1([C@@H](CNC(=O)CN2C(C3=CC=CC=C3N=N2)=O)C)=CC=CC=C1 NHHIFMSLOXYVBO-CYBMUJFWSA-N 0.000 claims 2
- POOIUAVPFUNLNL-NSHDSACASA-N 2-(5-fluoro-4-oxo-1,2,3-benzotriazin-3-yl)-N-[(1S)-1-(4-methoxyphenyl)ethyl]acetamide Chemical compound FC1=CC=CC=2N=NN(C(C=21)=O)CC(=O)N[C@@H](C)C1=CC=C(C=C1)OC POOIUAVPFUNLNL-NSHDSACASA-N 0.000 claims 2
- KCBGXCAHBBWRNE-ZDUSSCGKSA-N 2-(5-methoxy-4-oxo-1,2,3-benzotriazin-3-yl)-N-[(1S)-1-(4-methylphenyl)ethyl]acetamide Chemical compound COC1=CC=CC=2N=NN(C(C=21)=O)CC(=O)N[C@@H](C)C1=CC=C(C=C1)C KCBGXCAHBBWRNE-ZDUSSCGKSA-N 0.000 claims 2
- OIAZRITXWWPTNH-JTQLQIEISA-N 2-(6,8-dichloro-4-oxo-1,2,3-benzotriazin-3-yl)-N-[(1S)-1-(4-methoxyphenyl)ethyl]acetamide Chemical compound ClC1=CC2=C(N=NN(C2=O)CC(=O)N[C@@H](C)C2=CC=C(C=C2)OC)C(=C1)Cl OIAZRITXWWPTNH-JTQLQIEISA-N 0.000 claims 2
- QDKXIUDVKUIJBT-NSHDSACASA-N 2-(6,8-dichloro-4-oxo-1,2,3-benzotriazin-3-yl)-N-[(1S)-1-(4-methylphenyl)ethyl]acetamide Chemical compound ClC1=CC2=C(N=NN(C2=O)CC(=O)N[C@@H](C)C2=CC=C(C=C2)C)C(=C1)Cl QDKXIUDVKUIJBT-NSHDSACASA-N 0.000 claims 2
- BHDLUINLODALAW-AWEZNQCLSA-N 2-(6,8-dimethyl-4-oxo-1,2,3-benzotriazin-3-yl)-N-[(1S)-1-(4-methoxyphenyl)ethyl]acetamide Chemical compound CC1=CC2=C(N=NN(C2=O)CC(=O)N[C@@H](C)C2=CC=C(C=C2)OC)C(=C1)C BHDLUINLODALAW-AWEZNQCLSA-N 0.000 claims 2
- IMHMUHMELFJCBS-NSHDSACASA-N 2-(6-chloro-4-oxo-1,2,3-benzotriazin-3-yl)-N-[(1S)-1-(4-methoxyphenyl)ethyl]acetamide Chemical compound ClC1=CC2=C(N=NN(C2=O)CC(=O)N[C@@H](C)C2=CC=C(C=C2)OC)C=C1 IMHMUHMELFJCBS-NSHDSACASA-N 0.000 claims 2
- QTXLUZLLRISUJM-LBPRGKRZSA-N 2-(6-chloro-4-oxo-1,2,3-benzotriazin-3-yl)-N-[(1S)-1-(4-methylphenyl)ethyl]acetamide Chemical compound ClC1=CC2=C(N=NN(C2=O)CC(=O)N[C@@H](C)C2=CC=C(C=C2)C)C=C1 QTXLUZLLRISUJM-LBPRGKRZSA-N 0.000 claims 2
- POUOYHMMTHSEKJ-NSHDSACASA-N 2-(6-fluoro-4-oxo-1,2,3-benzotriazin-3-yl)-N-[(1S)-1-(4-methoxyphenyl)ethyl]acetamide Chemical compound FC1=CC2=C(N=NN(C2=O)CC(=O)N[C@@H](C)C2=CC=C(C=C2)OC)C=C1 POUOYHMMTHSEKJ-NSHDSACASA-N 0.000 claims 2
- JQVQDOAWGVPICK-LBPRGKRZSA-N 2-(6-fluoro-4-oxo-1,2,3-benzotriazin-3-yl)-N-[(1S)-1-(4-methylphenyl)ethyl]acetamide Chemical compound FC1=CC2=C(N=NN(C2=O)CC(=O)N[C@@H](C)C2=CC=C(C=C2)C)C=C1 JQVQDOAWGVPICK-LBPRGKRZSA-N 0.000 claims 2
- MPFIBOVPLHCEFO-ZDUSSCGKSA-N 2-(6-methoxy-4-oxo-1,2,3-benzotriazin-3-yl)-N-[(1S)-1-(4-methylphenyl)ethyl]acetamide Chemical compound COC1=CC2=C(N=NN(C2=O)CC(=O)N[C@@H](C)C2=CC=C(C=C2)C)C=C1 MPFIBOVPLHCEFO-ZDUSSCGKSA-N 0.000 claims 2
- MLWZRROZCADIQQ-AWEZNQCLSA-N 2-(6-methyl-4-oxo-1,2,3-benzotriazin-3-yl)-N-[(1S)-1-(4-methylphenyl)ethyl]acetamide Chemical compound CC1=CC2=C(N=NN(C2=O)CC(=O)N[C@@H](C)C2=CC=C(C=C2)C)C=C1 MLWZRROZCADIQQ-AWEZNQCLSA-N 0.000 claims 2
- REOWSJCKCYOYLG-LBPRGKRZSA-N 2-(7-chloro-4-oxo-1,2,3-benzotriazin-3-yl)-N-[(1S)-1-(4-methylphenyl)ethyl]acetamide Chemical compound ClC=1C=CC2=C(N=NN(C2=O)CC(=O)N[C@@H](C)C2=CC=C(C=C2)C)C=1 REOWSJCKCYOYLG-LBPRGKRZSA-N 0.000 claims 2
- KZGCQSLARYWBID-LBPRGKRZSA-N 2-(7-methoxy-4-oxo-1,2,3-benzotriazin-3-yl)-N-[(1S)-1-(4-methoxyphenyl)ethyl]acetamide Chemical compound COC=1C=CC2=C(N=NN(C2=O)CC(=O)N[C@@H](C)C2=CC=C(C=C2)OC)C=1 KZGCQSLARYWBID-LBPRGKRZSA-N 0.000 claims 2
- BFLNIJPZEKHHMD-ZDUSSCGKSA-N 2-(7-methoxy-4-oxo-1,2,3-benzotriazin-3-yl)-N-[(1S)-1-(4-methylphenyl)ethyl]acetamide Chemical compound COC=1C=CC2=C(N=NN(C2=O)CC(=O)N[C@@H](C)C2=CC=C(C=C2)C)C=1 BFLNIJPZEKHHMD-ZDUSSCGKSA-N 0.000 claims 2
- UOFXNHJSTFHCTF-AWEZNQCLSA-N 2-(7-methyl-4-oxo-1,2,3-benzotriazin-3-yl)-N-[(1S)-1-(4-methylphenyl)ethyl]acetamide Chemical compound CC=1C=CC2=C(N=NN(C2=O)CC(=O)N[C@@H](C)C2=CC=C(C=C2)C)C=1 UOFXNHJSTFHCTF-AWEZNQCLSA-N 0.000 claims 2
- XSLDKBATWMJNOE-NSHDSACASA-N 2-(8-chloro-4-oxo-1,2,3-benzotriazin-3-yl)-N-[(1S)-1-(4-methoxyphenyl)ethyl]acetamide Chemical compound ClC1=CC=CC2=C1N=NN(C2=O)CC(=O)N[C@@H](C)C1=CC=C(C=C1)OC XSLDKBATWMJNOE-NSHDSACASA-N 0.000 claims 2
- ZXFHIAAKONRMNN-LBPRGKRZSA-N 2-(8-chloro-4-oxo-1,2,3-benzotriazin-3-yl)-N-[(1S)-1-(4-methylphenyl)ethyl]acetamide Chemical compound ClC1=CC=CC2=C1N=NN(C2=O)CC(=O)N[C@@H](C)C1=CC=C(C=C1)C ZXFHIAAKONRMNN-LBPRGKRZSA-N 0.000 claims 2
- QIXCVVSWMRNBGV-NSHDSACASA-N 2-(8-fluoro-4-oxo-1,2,3-benzotriazin-3-yl)-N-[(1S)-1-(4-methoxyphenyl)ethyl]acetamide Chemical compound FC1=CC=CC2=C1N=NN(C2=O)CC(=O)N[C@@H](C)C1=CC=C(C=C1)OC QIXCVVSWMRNBGV-NSHDSACASA-N 0.000 claims 2
- NFHZMSKSZWDGLN-LBPRGKRZSA-N 2-(8-fluoro-4-oxo-1,2,3-benzotriazin-3-yl)-N-[(1S)-1-(4-methylphenyl)ethyl]acetamide Chemical compound FC1=CC=CC2=C1N=NN(C2=O)CC(=O)N[C@@H](C)C1=CC=C(C=C1)C NFHZMSKSZWDGLN-LBPRGKRZSA-N 0.000 claims 2
- BFNPBDJFKSZLHJ-ZDUSSCGKSA-N 2-(8-fluoro-6-methyl-4-oxo-1,2,3-benzotriazin-3-yl)-N-[(1S)-1-(4-methylphenyl)ethyl]acetamide Chemical compound FC1=CC(=CC2=C1N=NN(C2=O)CC(=O)N[C@@H](C)C1=CC=C(C=C1)C)C BFNPBDJFKSZLHJ-ZDUSSCGKSA-N 0.000 claims 2
- QEFZPGDVQARJQX-LBPRGKRZSA-N 2-(8-methoxy-4-oxo-1,2,3-benzotriazin-3-yl)-N-[(1S)-1-(4-methoxyphenyl)ethyl]acetamide Chemical compound COC1=CC=CC2=C1N=NN(C2=O)CC(=O)N[C@@H](C)C1=CC=C(C=C1)OC QEFZPGDVQARJQX-LBPRGKRZSA-N 0.000 claims 2
- QZHOUHZKMLGYJN-ZDUSSCGKSA-N 2-(8-methoxy-4-oxo-1,2,3-benzotriazin-3-yl)-N-[(1S)-1-(4-methylphenyl)ethyl]acetamide Chemical compound COC1=CC=CC2=C1N=NN(C2=O)CC(=O)N[C@@H](C)C1=CC=C(C=C1)C QZHOUHZKMLGYJN-ZDUSSCGKSA-N 0.000 claims 2
- UUUQJHYOVJWEKZ-AWEZNQCLSA-N 2-(8-methyl-4-oxo-1,2,3-benzotriazin-3-yl)-N-[(1S)-1-(4-methylphenyl)ethyl]acetamide Chemical compound CC1=CC=CC2=C1N=NN(C2=O)CC(=O)N[C@@H](C)C1=CC=C(C=C1)C UUUQJHYOVJWEKZ-AWEZNQCLSA-N 0.000 claims 2
- 208000036864 Attention deficit/hyperactivity disease Diseases 0.000 claims 2
- 208000020925 Bipolar disease Diseases 0.000 claims 2
- AMRDWWMUNNALHK-CYBMUJFWSA-N N-[(1R)-1-(4-methylphenyl)ethyl]-2-(4-oxo-1,2,3-benzotriazin-3-yl)acetamide Chemical compound O=C1C2=C(N=NN1CC(=O)N[C@H](C)C1=CC=C(C=C1)C)C=CC=C2 AMRDWWMUNNALHK-CYBMUJFWSA-N 0.000 claims 2
- SJQFFAMTFHKEGM-LBPRGKRZSA-N N-[(1S)-1-(2,4-dimethoxyphenyl)ethyl]-2-(4-oxo-1,2,3-benzotriazin-3-yl)acetamide Chemical compound COC1=C(C=CC(=C1)OC)[C@H](C)NC(CN1N=NC2=C(C1=O)C=CC=C2)=O SJQFFAMTFHKEGM-LBPRGKRZSA-N 0.000 claims 2
- LXZGSJQRZHHQBT-AWEZNQCLSA-N N-[(1S)-1-(2,4-dimethylphenyl)ethyl]-2-(4-oxo-1,2,3-benzotriazin-3-yl)acetamide Chemical compound CC1=C(C=CC(=C1)C)[C@H](C)NC(CN1N=NC2=C(C1=O)C=CC=C2)=O LXZGSJQRZHHQBT-AWEZNQCLSA-N 0.000 claims 2
- FVQNXYAXDJPHPI-ZDUSSCGKSA-N N-[(1S)-1-(2,4-dimethylphenyl)ethyl]-2-(6-fluoro-4-oxo-1,2,3-benzotriazin-3-yl)acetamide Chemical compound CC1=C(C=CC(=C1)C)[C@H](C)NC(CN1N=NC2=C(C1=O)C=C(C=C2)F)=O FVQNXYAXDJPHPI-ZDUSSCGKSA-N 0.000 claims 2
- DVGUHHIULIPPKB-LBPRGKRZSA-N N-[(1S)-1-(2-fluoro-4-methylphenyl)ethyl]-2-(4-oxo-1,2,3-benzotriazin-3-yl)acetamide Chemical compound FC1=C(C=CC(=C1)C)[C@H](C)NC(CN1N=NC2=C(C1=O)C=CC=C2)=O DVGUHHIULIPPKB-LBPRGKRZSA-N 0.000 claims 2
- FHQBSRAOVCISAR-ZDUSSCGKSA-N N-[(1S)-1-(2-methoxy-4-methylphenyl)ethyl]-2-(4-oxo-1,2,3-benzotriazin-3-yl)acetamide Chemical compound COC1=C(C=CC(=C1)C)[C@H](C)NC(CN1N=NC2=C(C1=O)C=CC=C2)=O FHQBSRAOVCISAR-ZDUSSCGKSA-N 0.000 claims 2
- YNTGGPUBNFJFLL-NSHDSACASA-N N-[(1S)-1-(4-bromophenyl)ethyl]-2-(4-oxo-1,2,3-benzotriazin-3-yl)acetamide Chemical compound BrC1=CC=C(C=C1)[C@H](C)NC(CN1N=NC2=C(C1=O)C=CC=C2)=O YNTGGPUBNFJFLL-NSHDSACASA-N 0.000 claims 2
- CWATUEVSJUJDCD-ZDUSSCGKSA-N N-[(1S)-1-(4-ethoxyphenyl)ethyl]-2-(4-oxo-1,2,3-benzotriazin-3-yl)acetamide Chemical compound C(C)OC1=CC=C(C=C1)[C@H](C)NC(CN1N=NC2=C(C1=O)C=CC=C2)=O CWATUEVSJUJDCD-ZDUSSCGKSA-N 0.000 claims 2
- MROVHIZKKLRMMY-LBPRGKRZSA-N N-[(1S)-1-(4-methoxyphenyl)ethyl]-2-(4-oxo-1,2,3-benzotriazin-3-yl)acetamide Chemical compound COC1=CC=C(C=C1)[C@H](C)NC(CN1N=NC2=C(C1=O)C=CC=C2)=O MROVHIZKKLRMMY-LBPRGKRZSA-N 0.000 claims 2
- RBQKTEXHVZWNOM-ZDUSSCGKSA-N N-[(1S)-1-(4-methoxyphenyl)ethyl]-2-(5-methyl-4-oxo-1,2,3-benzotriazin-3-yl)acetamide Chemical compound COC1=CC=C(C=C1)[C@H](C)NC(CN1N=NC2=C(C1=O)C(=CC=C2)C)=O RBQKTEXHVZWNOM-ZDUSSCGKSA-N 0.000 claims 2
- OOURTFAADXDITC-ZDUSSCGKSA-N N-[(1S)-1-(4-methoxyphenyl)ethyl]-2-(6-methyl-4-oxo-1,2,3-benzotriazin-3-yl)acetamide Chemical compound COC1=CC=C(C=C1)[C@H](C)NC(CN1N=NC2=C(C1=O)C=C(C=C2)C)=O OOURTFAADXDITC-ZDUSSCGKSA-N 0.000 claims 2
- FNEAIYYXBKHWMI-ZDUSSCGKSA-N N-[(1S)-1-(4-methoxyphenyl)ethyl]-2-(7-methyl-4-oxo-1,2,3-benzotriazin-3-yl)acetamide Chemical compound COC1=CC=C(C=C1)[C@H](C)NC(CN1N=NC2=C(C1=O)C=CC(=C2)C)=O FNEAIYYXBKHWMI-ZDUSSCGKSA-N 0.000 claims 2
- SPIRXYAZOIUKLW-ZDUSSCGKSA-N N-[(1S)-1-(4-methoxyphenyl)ethyl]-2-(8-methyl-4-oxo-1,2,3-benzotriazin-3-yl)acetamide Chemical compound COC1=CC=C(C=C1)[C@H](C)NC(CN1N=NC2=C(C1=O)C=CC=C2C)=O SPIRXYAZOIUKLW-ZDUSSCGKSA-N 0.000 claims 2
- AMRDWWMUNNALHK-ZDUSSCGKSA-N N-[(1S)-1-(4-methylphenyl)ethyl]-2-(4-oxo-1,2,3-benzotriazin-3-yl)acetamide Chemical compound O=C1C2=C(N=NN1CC(=O)N[C@@H](C)C1=CC=C(C=C1)C)C=CC=C2 AMRDWWMUNNALHK-ZDUSSCGKSA-N 0.000 claims 2
- WCYBVBQGXJOEJY-NSHDSACASA-N N-[(1S)-1-[4-(difluoromethoxy)phenyl]ethyl]-2-(4-oxo-1,2,3-benzotriazin-3-yl)acetamide Chemical compound FC(OC1=CC=C(C=C1)[C@H](C)NC(CN1N=NC2=C(C1=O)C=CC=C2)=O)F WCYBVBQGXJOEJY-NSHDSACASA-N 0.000 claims 2
- CBWQJOMWISNROA-NSHDSACASA-N N-[(1S)-1-[4-(difluoromethoxy)phenyl]ethyl]-2-(5-methoxy-4-oxo-1,2,3-benzotriazin-3-yl)acetamide Chemical compound FC(OC1=CC=C(C=C1)[C@H](C)NC(CN1N=NC2=C(C1=O)C(=CC=C2)OC)=O)F CBWQJOMWISNROA-NSHDSACASA-N 0.000 claims 2
- NVBVBYBGSGRJPA-JTQLQIEISA-N N-[(1S)-1-[4-(difluoromethoxy)phenyl]ethyl]-2-(6-fluoro-4-oxo-1,2,3-benzotriazin-3-yl)acetamide Chemical compound FC(OC1=CC=C(C=C1)[C@H](C)NC(CN1N=NC2=C(C1=O)C=C(C=C2)F)=O)F NVBVBYBGSGRJPA-JTQLQIEISA-N 0.000 claims 2
- VDXSDOHBTDMGFG-CYBMUJFWSA-N N-[(2R)-1-(4-methoxyphenyl)propan-2-yl]-2-(4-oxo-1,2,3-benzotriazin-3-yl)acetamide Chemical compound COC1=CC=C(C=C1)C[C@@H](C)NC(CN1N=NC2=C(C1=O)C=CC=C2)=O VDXSDOHBTDMGFG-CYBMUJFWSA-N 0.000 claims 2
- VDXSDOHBTDMGFG-ZDUSSCGKSA-N N-[(2S)-1-(4-methoxyphenyl)propan-2-yl]-2-(4-oxo-1,2,3-benzotriazin-3-yl)acetamide Chemical compound COC1=CC=C(C=C1)C[C@H](C)NC(CN1N=NC2=C(C1=O)C=CC=C2)=O VDXSDOHBTDMGFG-ZDUSSCGKSA-N 0.000 claims 2
- 208000015802 attention deficit-hyperactivity disease Diseases 0.000 claims 2
- 208000029560 autism spectrum disease Diseases 0.000 claims 2
- 201000010099 disease Diseases 0.000 claims 2
- 208000035475 disorder Diseases 0.000 claims 2
- 206010013663 drug dependence Diseases 0.000 claims 2
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 claims 2
- 201000000980 schizophrenia Diseases 0.000 claims 2
- LQEAGUMJDIWZGQ-HNNXBMFYSA-N 2-(4-oxo-1,2,3-benzotriazin-3-yl)-N-[(1S)-1-[4-(trifluoromethoxy)phenyl]propyl]acetamide Chemical compound O=C1C2=C(N=NN1CC(=O)N[C@@H](CC)C1=CC=C(C=C1)OC(F)(F)F)C=CC=C2 LQEAGUMJDIWZGQ-HNNXBMFYSA-N 0.000 claims 1
- IXZCMRONQCIGHM-HNNXBMFYSA-N 2-(4-oxo-1,2,3-benzotriazin-3-yl)-N-[(1S)-1-[4-(trifluoromethyl)phenyl]propyl]acetamide Chemical compound O=C1C2=C(N=NN1CC(=O)N[C@@H](CC)C1=CC=C(C=C1)C(F)(F)F)C=CC=C2 IXZCMRONQCIGHM-HNNXBMFYSA-N 0.000 claims 1
- FTLWUWIALIQVHE-UHFFFAOYSA-N 2-(4-oxo-1,2,3-benzotriazin-3-yl)-n-(2-phenylethyl)acetamide Chemical compound N1=NC2=CC=CC=C2C(=O)N1CC(=O)NCCC1=CC=CC=C1 FTLWUWIALIQVHE-UHFFFAOYSA-N 0.000 claims 1
- PGSIBSVOWOZOCM-LBPRGKRZSA-N 2-(4-oxo-1,2,3-benzotriazin-3-yl)-n-[(1s)-1-phenylethyl]acetamide Chemical compound C1([C@@H](NC(=O)CN2C(C3=CC=CC=C3N=N2)=O)C)=CC=CC=C1 PGSIBSVOWOZOCM-LBPRGKRZSA-N 0.000 claims 1
- GOUPEUKVQKMWGR-LBPRGKRZSA-N 2-(5-fluoro-4-oxo-1,2,3-benzotriazin-3-yl)-N-[(1S)-1-(4-methylphenyl)ethyl]acetamide Chemical compound FC1=CC=CC=2N=NN(C(C=21)=O)CC(=O)N[C@@H](C)C1=CC=C(C=C1)C GOUPEUKVQKMWGR-LBPRGKRZSA-N 0.000 claims 1
- KNJBLSXPWYUHOB-LBPRGKRZSA-N 2-(5-methoxy-4-oxo-1,2,3-benzotriazin-3-yl)-N-[(1S)-1-(4-methoxyphenyl)ethyl]acetamide Chemical compound COC1=CC=CC=2N=NN(C(C=21)=O)CC(=O)N[C@@H](C)C1=CC=C(C=C1)OC KNJBLSXPWYUHOB-LBPRGKRZSA-N 0.000 claims 1
- CPHXLFKIUVVIOQ-UHFFFAOYSA-N 2-(trifluoromethoxy)benzaldehyde Chemical group FC(F)(F)OC1=CC=CC=C1C=O CPHXLFKIUVVIOQ-UHFFFAOYSA-N 0.000 claims 1
- IQHSSYROJYPFDV-UHFFFAOYSA-N 2-bromo-1,3-dichloro-5-(trifluoromethyl)benzene Chemical group FC(F)(F)C1=CC(Cl)=C(Br)C(Cl)=C1 IQHSSYROJYPFDV-UHFFFAOYSA-N 0.000 claims 1
- 125000001255 4-fluorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1F 0.000 claims 1
- 208000019901 Anxiety disease Diseases 0.000 claims 1
- 208000028698 Cognitive impairment Diseases 0.000 claims 1
- 206010013654 Drug abuse Diseases 0.000 claims 1
- 208000030814 Eating disease Diseases 0.000 claims 1
- 208000019454 Feeding and Eating disease Diseases 0.000 claims 1
- 208000001640 Fibromyalgia Diseases 0.000 claims 1
- LSDUJHSPSQGFJM-UHFFFAOYSA-N N-(5-methyl-4-oxo-1,2,3-benzotriazin-3-yl)acetamide Chemical compound C(C)(=O)NN1N=NC2=C(C1=O)C(=CC=C2)C LSDUJHSPSQGFJM-UHFFFAOYSA-N 0.000 claims 1
- ZKALVEIABNRJPU-ZDUSSCGKSA-N N-[(1S)-1-(2-methylphenyl)ethyl]-2-(4-oxo-1,2,3-benzotriazin-3-yl)acetamide Chemical compound O=C1C2=C(N=NN1CC(=O)N[C@@H](C)C1=C(C=CC=C1)C)C=CC=C2 ZKALVEIABNRJPU-ZDUSSCGKSA-N 0.000 claims 1
- GMLBGSJQDOOBRU-LBPRGKRZSA-N N-[(1S)-1-(4-methylphenyl)ethyl]-2-[4-oxo-6-(trifluoromethyl)-1,2,3-benzotriazin-3-yl]acetamide Chemical compound O=C1C2=C(N=NN1CC(=O)N[C@@H](C)C1=CC=C(C=C1)C)C=CC(=C2)C(F)(F)F GMLBGSJQDOOBRU-LBPRGKRZSA-N 0.000 claims 1
- NCYGXXHWJXKIOW-UHFFFAOYSA-N N-[2-(2-chloro-4-methoxyphenyl)ethyl]-2-(4-oxo-1,2,3-benzotriazin-3-yl)acetamide Chemical compound ClC1=C(CCNC(CN2N=NC3=C(C2=O)C=CC=C3)=O)C=CC(=C1)OC NCYGXXHWJXKIOW-UHFFFAOYSA-N 0.000 claims 1
- RTUBUXQAHORXQB-UHFFFAOYSA-N N-[2-(4-hydroxyphenyl)ethyl]-2-(4-oxo-1,2,3-benzotriazin-3-yl)acetamide Chemical compound OC1=CC=C(C=C1)CCNC(CN1N=NC2=C(C1=O)C=CC=C2)=O RTUBUXQAHORXQB-UHFFFAOYSA-N 0.000 claims 1
- ZGZJPRGEZGGMOK-UHFFFAOYSA-N N-[2-(4-methoxyphenyl)ethyl]-N-methyl-2-(4-oxo-1,2,3-benzotriazin-3-yl)acetamide Chemical compound COC1=CC=C(C=C1)CCN(C(CN1N=NC2=C(C1=O)C=CC=C2)=O)C ZGZJPRGEZGGMOK-UHFFFAOYSA-N 0.000 claims 1
- RHLQOJVKJGYHQZ-UHFFFAOYSA-N N-[2-(4-methylphenyl)ethyl]-2-(4-oxo-1,2,3-benzotriazin-3-yl)acetamide Chemical compound CC1=CC=C(C=C1)CCNC(CN1N=NC2=C(C1=O)C=CC=C2)=O RHLQOJVKJGYHQZ-UHFFFAOYSA-N 0.000 claims 1
- 208000021384 Obsessive-Compulsive disease Diseases 0.000 claims 1
- 208000002193 Pain Diseases 0.000 claims 1
- 239000013543 active substance Substances 0.000 claims 1
- 125000001309 chloro group Chemical group Cl* 0.000 claims 1
- 208000010877 cognitive disease Diseases 0.000 claims 1
- 235000014632 disordered eating Nutrition 0.000 claims 1
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims 1
- BRVHTHJIFYTNJL-NSHDSACASA-N n-[(1s)-1-(4-chlorophenyl)ethyl]-2-(4-oxo-1,2,3-benzotriazin-3-yl)acetamide Chemical compound C1([C@@H](NC(=O)CN2C(C3=CC=CC=C3N=N2)=O)C)=CC=C(Cl)C=C1 BRVHTHJIFYTNJL-NSHDSACASA-N 0.000 claims 1
- IKWQWSKSKJKRIZ-NSHDSACASA-N n-[(1s)-1-(4-fluorophenyl)ethyl]-2-(4-oxo-1,2,3-benzotriazin-3-yl)acetamide Chemical compound C1([C@@H](NC(=O)CN2C(C3=CC=CC=C3N=N2)=O)C)=CC=C(F)C=C1 IKWQWSKSKJKRIZ-NSHDSACASA-N 0.000 claims 1
- CPFFDGFFVKSWCC-UHFFFAOYSA-N n-[2-(3-chlorophenyl)ethyl]-2-(4-oxo-1,2,3-benzotriazin-3-yl)acetamide Chemical compound ClC1=CC=CC(CCNC(=O)CN2C(C3=CC=CC=C3N=N2)=O)=C1 CPFFDGFFVKSWCC-UHFFFAOYSA-N 0.000 claims 1
- GASJSONKGOIOOV-UHFFFAOYSA-N n-[2-(4-chlorophenyl)ethyl]-2-(4-oxo-1,2,3-benzotriazin-3-yl)acetamide Chemical compound C1=CC(Cl)=CC=C1CCNC(=O)CN1C(=O)C2=CC=CC=C2N=N1 GASJSONKGOIOOV-UHFFFAOYSA-N 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 239000000825 pharmaceutical preparation Substances 0.000 claims 1
- 229940127557 pharmaceutical product Drugs 0.000 claims 1
- 208000028173 post-traumatic stress disease Diseases 0.000 claims 1
- 208000019116 sleep disease Diseases 0.000 claims 1
- 208000020685 sleep-wake disease Diseases 0.000 claims 1
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2019229837A JP6918088B2 (ja) | 2014-11-20 | 2019-12-20 | Ｇｐｒ１３９のモジュレーターとしての４−オキソ−３，４−ジヒドロ−１，２，３−ベンゾトリアジン |
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201462082539P | 2014-11-20 | 2014-11-20 | |
| US62/082,539 | 2014-11-20 | ||
| US201562184729P | 2015-06-25 | 2015-06-25 | |
| US62/184,729 | 2015-06-25 | ||
| PCT/US2015/061607 WO2016081736A1 (en) | 2014-11-20 | 2015-11-19 | 4-oxo-3,4-dihydro-1,2,3-benzotriazines as modulators of gpr139 |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019229837A Division JP6918088B2 (ja) | 2014-11-20 | 2019-12-20 | Ｇｐｒ１３９のモジュレーターとしての４−オキソ−３，４−ジヒドロ−１，２，３−ベンゾトリアジン |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2017535559A JP2017535559A (ja) | 2017-11-30 |
| JP2017535559A5 true JP2017535559A5 (cg-RX-API-DMAC7.html) | 2018-12-27 |
| JP6637501B2 JP6637501B2 (ja) | 2020-01-29 |
Family
ID=55022667
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017526844A Active JP6637501B2 (ja) | 2014-11-20 | 2015-11-19 | Ｇｐｒ１３９のモジュレーターとしての４−オキソ−３，４−ジヒドロ−１，２，３−ベンゾトリアジン |
| JP2019229837A Active JP6918088B2 (ja) | 2014-11-20 | 2019-12-20 | Ｇｐｒ１３９のモジュレーターとしての４−オキソ−３，４−ジヒドロ−１，２，３−ベンゾトリアジン |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019229837A Active JP6918088B2 (ja) | 2014-11-20 | 2019-12-20 | Ｇｐｒ１３９のモジュレーターとしての４−オキソ−３，４−ジヒドロ−１，２，３−ベンゾトリアジン |
Country Status (40)
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JO3719B1 (ar) | 2014-11-20 | 2021-01-31 | Takeda Pharmaceuticals Co | 4- أوكسو-4،3- داي هيدرو-3،2،1- بنزوترايازينات كمواد ضابطة لأجل gpr139 |
| WO2020081538A1 (en) | 2018-10-16 | 2020-04-23 | The Scripps Research Institute | Methods related to opioid therapeutics |
| WO2020097609A1 (en) * | 2018-11-09 | 2020-05-14 | Blackthorn Therapeutics, Inc. | Gpr139 receptor modulators |
| AR119971A1 (es) * | 2019-09-16 | 2022-01-26 | Takeda Pharmaceuticals Co | Derivados de piridazin-3(2h)-ona fusionados con azol |
| WO2021127459A1 (en) * | 2019-12-20 | 2021-06-24 | Blackthorn Therapeutics, Inc. | Gpr139 receptor modulators |
| JP7697974B2 (ja) * | 2020-05-08 | 2025-06-24 | 武田薬品工業株式会社 | Ｇｐｒ１３９アゴニストの置換ベンゾトリアジノン代謝物 |
| EP4213853A1 (en) * | 2020-09-21 | 2023-07-26 | Takeda Pharmaceutical Company Limited | Treatment for schizophrenia |
| US11760788B2 (en) | 2021-03-02 | 2023-09-19 | Pathways Neuro Pharma, Inc. | Neuroreceptor compositions and methods of use |
| CN116693536A (zh) * | 2022-03-01 | 2023-09-05 | 上海科技大学 | 吡咯并三嗪酮类化合物、含其的药物组合物、其制备方法及其应用 |
| WO2023165262A1 (zh) * | 2022-03-01 | 2023-09-07 | 上海科技大学 | 噻吩并含氮杂环类化合物、含其的药物组合物、其制备方法及其应用 |
| CN117986183A (zh) * | 2022-10-28 | 2024-05-07 | 浙江友宁生物医药科技有限公司 | 一种gpr139受体激动剂、其制备方法及其应用 |
| WO2024102802A1 (en) * | 2022-11-11 | 2024-05-16 | Takeda Pharmaceutical Company Limited | Zelatriazin for the treatment of depression |
| WO2025119351A1 (zh) * | 2023-12-08 | 2025-06-12 | 深圳湾实验室 | Gpr139激动剂 |
| WO2025162441A1 (zh) * | 2024-02-02 | 2025-08-07 | 上海科技大学 | 稠杂环类化合物与其制备方法、药物组合物及应用 |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3794726A (en) * | 1972-08-21 | 1974-02-26 | Uniroyal Inc | Inhibiting aggressive behavior with 1,2,3-benzotriazin-(3h)-one |
| DE3752141T2 (de) | 1986-02-24 | 1998-03-26 | Mitsui Petrochemical Ind | Mittel zur behandlung von neuropathie |
| ATE108791T1 (de) * | 1987-11-04 | 1994-08-15 | Beecham Group Plc | Neue 4-oxobenzotriazine und 4-oxochinazoline. |
| WO2004108673A2 (en) | 2003-06-09 | 2004-12-16 | Boehringer Ingelheim International Gmbh | Inhibitors of papilloma virus |
| WO2005011611A2 (en) | 2003-07-31 | 2005-02-10 | Irm, Llc | Bicyclic compounds and compositions as pdf inhibitors |
| FR2875805B1 (fr) | 2004-09-27 | 2006-12-29 | Genfit S A | Composes derives de n-(benzyl) phenylacetamide substitues, preparation et utilisations |
| TW200736227A (en) | 2005-12-23 | 2007-10-01 | Astrazeneca Ab | New compounds III |
| TWI433839B (zh) | 2006-08-11 | 2014-04-11 | Neomed Inst | 新穎的苯并咪唑衍生物290 |
| CA2680775A1 (en) * | 2007-03-23 | 2008-10-02 | F. Hoffmann-La Roche Ag | Aza-pyridopyrimidinone derivatives |
| CA2709784A1 (en) * | 2007-12-21 | 2009-07-09 | University Of Rochester | Method for altering the lifespan of eukaryotic organisms |
| WO2011138265A2 (en) | 2010-05-03 | 2011-11-10 | Evotec Ag | Indole and indazole derivatives as orexin receptor antagonists |
| HK1220622A1 (zh) | 2013-03-14 | 2017-05-12 | Janssen Pharmaceutica, N.V. | Gpr139的生理性配体 |
| JO3719B1 (ar) * | 2014-11-20 | 2021-01-31 | Takeda Pharmaceuticals Co | 4- أوكسو-4،3- داي هيدرو-3،2،1- بنزوترايازينات كمواد ضابطة لأجل gpr139 |
-
2015
- 2015-11-18 JO JOP/2015/0282A patent/JO3719B1/ar active
- 2015-11-19 LT LTEP19152036.0T patent/LT3536324T/lt unknown
- 2015-11-19 SG SG11201704002UA patent/SG11201704002UA/en unknown
- 2015-11-19 EA EA201791096A patent/EA033728B1/ru unknown
- 2015-11-19 CR CR20170275A patent/CR20170275A/es unknown
- 2015-11-19 MA MA40993A patent/MA40993B1/fr unknown
- 2015-11-19 HR HRP20212009TT patent/HRP20212009T1/hr unknown
- 2015-11-19 HU HUE15816275A patent/HUE044145T2/hu unknown
- 2015-11-19 DK DK19152036.0T patent/DK3536324T3/da active
- 2015-11-19 ES ES15816275T patent/ES2734735T3/es active Active
- 2015-11-19 KR KR1020177016973A patent/KR102582021B1/ko active Active
- 2015-11-19 AU AU2015349866A patent/AU2015349866B2/en active Active
- 2015-11-19 MY MYPI2017701778A patent/MY187423A/en unknown
- 2015-11-19 EP EP15816275.0A patent/EP3221298B1/en active Active
- 2015-11-19 TW TW104138295A patent/TWI684590B/zh active
- 2015-11-19 SI SI201530772T patent/SI3221298T1/sl unknown
- 2015-11-19 UA UAA201705041A patent/UA120375C2/uk unknown
- 2015-11-19 DK DK15816275.0T patent/DK3221298T3/da active
- 2015-11-19 PT PT191520360T patent/PT3536324T/pt unknown
- 2015-11-19 MD MDE20170117 patent/MD3221298T2/ro unknown
- 2015-11-19 SM SM20220142T patent/SMT202200142T1/it unknown
- 2015-11-19 SI SI201531729T patent/SI3536324T1/sl unknown
- 2015-11-19 RS RS20190776A patent/RS59078B1/sr unknown
- 2015-11-19 UY UY0001036406A patent/UY36406A/es not_active Application Discontinuation
- 2015-11-19 CN CN202010988947.3A patent/CN112062730B/zh active Active
- 2015-11-19 EP EP19152036.0A patent/EP3536324B1/en active Active
- 2015-11-19 SM SM20190355T patent/SMT201900355T1/it unknown
- 2015-11-19 PE PE2017000866A patent/PE20170899A1/es unknown
- 2015-11-19 PL PL15816275T patent/PL3221298T3/pl unknown
- 2015-11-19 HR HRP20191003TT patent/HRP20191003T1/hr unknown
- 2015-11-19 PT PT15816275T patent/PT3221298T/pt unknown
- 2015-11-19 CN CN201580071393.8A patent/CN107108531B/zh active Active
- 2015-11-19 JP JP2017526844A patent/JP6637501B2/ja active Active
- 2015-11-19 TN TN2017000196A patent/TN2017000196A1/en unknown
- 2015-11-19 PL PL19152036T patent/PL3536324T3/pl unknown
- 2015-11-19 WO PCT/US2015/061607 patent/WO2016081736A1/en not_active Ceased
- 2015-11-19 GE GEAP201514515A patent/GEP20196961B/en unknown
- 2015-11-19 ES ES19152036T patent/ES2897545T3/es active Active
- 2015-11-19 NZ NZ732208A patent/NZ732208A/en unknown
- 2015-11-19 LT LTEP15816275.0T patent/LT3221298T/lt unknown
- 2015-11-19 US US14/946,194 patent/US9556130B2/en active Active
- 2015-11-19 CA CA2968242A patent/CA2968242C/en active Active
- 2015-11-19 RS RS20211398A patent/RS62563B1/sr unknown
- 2015-11-19 MX MX2017006448A patent/MX378158B/es unknown
- 2015-11-19 HU HUE19152036A patent/HUE057451T2/hu unknown
-
2016
- 2016-12-16 US US15/382,490 patent/US9770450B2/en active Active
-
2017
- 2017-05-12 DO DO2017000120A patent/DOP2017000120A/es unknown
- 2017-05-16 IL IL252311A patent/IL252311B/en active IP Right Grant
- 2017-05-18 PH PH12017500920A patent/PH12017500920B1/en unknown
- 2017-05-19 CL CL2017001292A patent/CL2017001292A1/es unknown
- 2017-06-16 CO CONC2017/0005959A patent/CO2017005959A2/es unknown
- 2017-06-20 EC ECIEPI201738999A patent/ECSP17038999A/es unknown
- 2017-08-22 US US15/683,589 patent/US10159677B2/en active Active
-
2018
- 2018-11-02 US US16/179,709 patent/US10561662B2/en active Active
-
2019
- 2019-06-20 CY CY20191100646T patent/CY1122613T1/el unknown
- 2019-12-20 JP JP2019229837A patent/JP6918088B2/ja active Active
-
2020
- 2020-01-02 US US16/732,536 patent/US11173161B2/en active Active
-
2021
- 2021-12-17 CY CY20211101111T patent/CY1124929T1/el unknown